Matteo Angelo Manini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Matteo Angelo Manini has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Angelo Sangiovanni
Division of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
6 shared publications - Massimo Iavarone
Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
6 shared publications Guido Ronchi
3 shared publicationsMassimo Colombo
A.M. & A. Migliavacca Center for Liver Disease and 1st Division of Gastroenterology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
3 shared publications- Antonio Grieco
Department of Medical and Surgical Sciences, CEMAD, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Rome, Italy
2 shared publications Cristina Della Corte
A.M. & A. Migliavacca Center for Liver Disease, 1st Division of Gastroenterology, Fondazione IRCCS Ca’ Granda Policlinico Hospital, University of Milan, Italy
2 shared publications
Latest Publications
- 4 January 2020
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 26 (4) , 507-516
Outcomes of Liver Transplant for Adults With Wilson’s Disease
Wilson’s disease (WD) is a rare genetic disorder with protean manifestations. Even if liver transplantation (LT) could represent an effective therapeutic option for patients with end‐stage liver disease, it has remained controversial in the presence of neuropsychiatric involvement. This study aimed to examine the frequency of adult LT for WD in Italy, focusing on the disease phenotype at the time of LT. A retrospective, observational, multicenter study was conducted across Italy exploring the frequency and characteristics of adults transplanted for WD between 2006 and 2016. A total of 29 adult WD patients underwent LT during the study period at 11 Italian LT centers (accounting for 0.4% of all LTs performed), and 27 of them were considered in this analysis (male/female, n = 9/18; age at LT, 29 years [19‐60 years]; median Model for End‐Stage Liver Disease score at LT, 27 [6‐49]). Isolated hepatic phenotype was the indication for LT in 17 (63%) patients, whereas 2 (7%) patients underwent LT for neurological impairment on compensated liver disease. Overall 1‐ and 5‐year patient survival was excellent (88% and 83%, respectively). Neuropsychiatric symptoms early after LT completely recovered in only a few patients. In conclusion, WD remains an uncommon, unusual indication for LT in Italy, displaying good post‐LT graft and patient survival. Because isolated neuropsychiatric involvement represents a rare indication to LT, more data are needed to properly assess the value of LT for WD in this subset of patients.
- 4 January 2020
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 26 (4) , 507-516
Outcomes of Liver Transplant for Adults With Wilson’s Disease
Wilson’s disease (WD) is a rare genetic disorder with protean manifestations. Even if liver transplantation (LT) could represent an effective therapeutic option for patients with end‐stage liver disease, it has remained controversial in the presence of neuropsychiatric involvement. This study aimed to examine the frequency of adult LT for WD in Italy, focusing on the disease phenotype at the time of LT. A retrospective, observational, multicenter study was conducted across Italy exploring the frequency and characteristics of adults transplanted for WD between 2006 and 2016. A total of 29 adult WD patients underwent LT during the study period at 11 Italian LT centers (accounting for 0.4% of all LTs performed), and 27 of them were considered in this analysis (male/female, n = 9/18; age at LT, 29 years [19‐60 years]; median Model for End‐Stage Liver Disease score at LT, 27 [6‐49]). Isolated hepatic phenotype was the indication for LT in 17 (63%) patients, whereas 2 (7%) patients underwent LT for neurological impairment on compensated liver disease. Overall 1‐ and 5‐year patient survival was excellent (88% and 83%, respectively). Neuropsychiatric symptoms early after LT completely recovered in only a few patients. In conclusion, WD remains an uncommon, unusual indication for LT in Italy, displaying good post‐LT graft and patient survival. Because isolated neuropsychiatric involvement represents a rare indication to LT, more data are needed to properly assess the value of LT for WD in this subset of patients.
- Open Access
- 31 July 2019
- Published by Elsevier in American Journal of Transplantation
- Vol. 19 (11) , 3176-3184
Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation
- 31 July 2019
- Published by Elsevier in American Journal of Transplantation
- Vol. 19 (11) , 3176-3184
Open AccessPreliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation
- Open Access
- 1 September 2018
- Published by Elsevier in Digestive and Liver Disease
- Vol. 50 (9) , 944-953
Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal
- 1 September 2018
- Published by Elsevier in Digestive and Liver Disease
- Vol. 50 (9) , 944-953
Open AccessEntecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal
- 20 November 2015
- Published by Elsevier in Digestive and Liver Disease
- Vol. 48 (1) , 94-96
Risk of hepatocellular carcinoma in relation to ABO blood type
- 20 November 2015
- Published by Elsevier in Digestive and Liver Disease
- Vol. 48 (1) , 94-96
Risk of hepatocellular carcinoma in relation to ABO blood type
- Open Access
- 13 June 2015
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 21 (10) , 1259-1269
Transarterial chemoembolization with drug‐eluting beads is effective for the maintenance of the Milan‐in status in patients with a small hepatocellular carcinoma
Transarterial chemoembolization (TACE) is the standard of care for the treatment of patients with an intermediate (Barcelona Clinic Liver Cancer [BCLC] B) hepatocellular carcinoma and to bridge patients with an early cancer to liver transplantation (LT). We explored the efficacy of TACE with drug‐eluting beads (DEB) in BCLC A patients. Included are all BCLC A patients unsuitable for resection or locoregional ablation who underwent a DEB TACE between 2006 and 2012. Treatment was carried out “a la demande” until complete tumor devascularization or progression beyond Milan criteria. In patients with a complete response (CR), a contrast computed tomography (CT) scan was repeated at 3‐month intervals during the first 2 years and then every 6 months alternating with abdominal ultrasound in the subsequent 3 years. Fifty‐five patients had 79 tumor nodules ranging 7 to 50 mm; 32 (58%) achieved a CR that was maintained up to 4 and 7 months in 21 (38%) and 17 (31%) patients, respectively. The 24‐ and 36‐month tumor‐free survivals were 21% and 9%, respectively. The overall cumulative progression beyond Milan criteria at 3, 6, 12, and 24 months was 2%, 5%, 30%, and 54%. LT eligibility was maintained for a median of 19 months (range, 2‐63 months). CR to first TACE was the strongest independent predictor of Milan‐in maintenance. In conclusion, DEB TACE may effectively bridge patients with an early cancer to LT, and a CR to the first procedure may guide patient prioritization during the waiting list.Liver Transpl 21:1259‐1269, 2015. © 2015 AASLD.
- 13 June 2015
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 21 (10) , 1259-1269
Open AccessTransarterial chemoembolization with drug‐eluting beads is effective for the maintenance of the Milan‐in status in patients with a small hepatocellular carcinoma
Transarterial chemoembolization (TACE) is the standard of care for the treatment of patients with an intermediate (Barcelona Clinic Liver Cancer [BCLC] B) hepatocellular carcinoma and to bridge patients with an early cancer to liver transplantation (LT). We explored the efficacy of TACE with drug‐eluting beads (DEB) in BCLC A patients. Included are all BCLC A patients unsuitable for resection or locoregional ablation who underwent a DEB TACE between 2006 and 2012. Treatment was carried out “a la demande” until complete tumor devascularization or progression beyond Milan criteria. In patients with a complete response (CR), a contrast computed tomography (CT) scan was repeated at 3‐month intervals during the first 2 years and then every 6 months alternating with abdominal ultrasound in the subsequent 3 years. Fifty‐five patients had 79 tumor nodules ranging 7 to 50 mm; 32 (58%) achieved a CR that was maintained up to 4 and 7 months in 21 (38%) and 17 (31%) patients, respectively. The 24‐ and 36‐month tumor‐free survivals were 21% and 9%, respectively. The overall cumulative progression beyond Milan criteria at 3, 6, 12, and 24 months was 2%, 5%, 30%, and 54%. LT eligibility was maintained for a median of 19 months (range, 2‐63 months). CR to first TACE was the strongest independent predictor of Milan‐in maintenance. In conclusion, DEB TACE may effectively bridge patients with an early cancer to LT, and a CR to the first procedure may guide patient prioritization during the waiting list.Liver Transpl 21:1259‐1269, 2015. © 2015 AASLD.
- 1 May 2014
- Published by Elsevier in Journal of Hepatology
- Vol. 60 (5) , 995-1001
Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma
- 1 May 2014
- Published by Elsevier in Journal of Hepatology
- Vol. 60 (5) , 995-1001
Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma
- Open Access
- 13 June 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (6) , e65238
Early and Late De Novo Tumors after Liver Transplantation in Adults: The Late Onset of Bladder Tumors in Men
De novo tumors (DNT) after liver transplantation (LT) represent a growing concern. We analyzed the incidence of DNT, type, time of onset, risk factors and mortality (as of 2010) in 494 adult patients transplanted in the last 26 years (1983–2009). DNT occurred in 41 (8.3%) of the patients. The Standardized Incidence Ratio (SIR) compared with the Italian population was 1.8. There was a higher incidence in males (SIR 2.0), an expected extremely high rate of Kaposi’s sarcoma (SIR 127.95) and unexpected higher rates of tumors of the bladder in males (SIR 3.3). The incidence of DNT was higher within the first two years of LT (SIR 2.7) for Kaposi’s sarcoma (SIR 393.3) and after 10 years (SIR 1.7) for bladder tumors (SIR 10.6). Multivariate analysis identified alcoholic cirrhosis (HR = 3.0, 95% CI = 1.2–7.8) and sclerosing cholangitis (HR = 3.5, 95% CI = 1.1–11.3) in the recipient as main risk factors for the occurrence of DNT. Surveillance protocols for DNT must be specifically oriented to patients transplanted for alcoholic cirrhosis and sclerosing cholangitis. They should focus on early detection of Kaposi’s sarcomas, and more remarkably, on late development bladder tumors in men after LT.
- 13 June 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (6) , e65238
Open AccessEarly and Late De Novo Tumors after Liver Transplantation in Adults: The Late Onset of Bladder Tumors in Men
De novo tumors (DNT) after liver transplantation (LT) represent a growing concern. We analyzed the incidence of DNT, type, time of onset, risk factors and mortality (as of 2010) in 494 adult patients transplanted in the last 26 years (1983–2009). DNT occurred in 41 (8.3%) of the patients. The Standardized Incidence Ratio (SIR) compared with the Italian population was 1.8. There was a higher incidence in males (SIR 2.0), an expected extremely high rate of Kaposi’s sarcoma (SIR 127.95) and unexpected higher rates of tumors of the bladder in males (SIR 3.3). The incidence of DNT was higher within the first two years of LT (SIR 2.7) for Kaposi’s sarcoma (SIR 393.3) and after 10 years (SIR 1.7) for bladder tumors (SIR 10.6). Multivariate analysis identified alcoholic cirrhosis (HR = 3.0, 95% CI = 1.2–7.8) and sclerosing cholangitis (HR = 3.5, 95% CI = 1.1–11.3) in the recipient as main risk factors for the occurrence of DNT. Surveillance protocols for DNT must be specifically oriented to patients transplanted for alcoholic cirrhosis and sclerosing cholangitis. They should focus on early detection of Kaposi’s sarcomas, and more remarkably, on late development bladder tumors in men after LT.
- Open Access
- 1 April 2013
- Published by Elsevier in Journal of Hepatology
- Vol. 58, S48
108 A NOVEL MODEL OF PRIORITY ASSESSMENT FOR PATIENTS WITH AND WITHOUT HEPATOCELLULAR CARCINOMA ON A COMMON LIVER TRANSPLANT WAITING LIST: A MULTICENTRE, COHORT STUDY
- 1 April 2013
- Published by Elsevier in Journal of Hepatology
- Vol. 58, S48
Open Access108 A NOVEL MODEL OF PRIORITY ASSESSMENT FOR PATIENTS WITH AND WITHOUT HEPATOCELLULAR CARCINOMA ON A COMMON LIVER TRANSPLANT WAITING LIST: A MULTICENTRE, COHORT STUDY
- 1 January 2013
- Published by Elsevier in Digestive and Liver Disease
- Vol. 45 (1) , 43-49
Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis
- 1 January 2013
- Published by Elsevier in Digestive and Liver Disease
- Vol. 45 (1) , 43-49
Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis
- Open Access
- 5 December 2012
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 68 (4) , 974-975
Twelve week post-treatment undetectable hepatitis C virus (HCV)-RNA by PCR assay predicts a sustained virological response to anti-HCV therapy independently from immunological status of the infected patients
- 5 December 2012
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 68 (4) , 974-975
Open AccessTwelve week post-treatment undetectable hepatitis C virus (HCV)-RNA by PCR assay predicts a sustained virological response to anti-HCV therapy independently from immunological status of the infected patients